SAFETY DATA SHEET
Mometasone Ointment Formulation

Version: 2.1
Revision Date: 10.10.2020
SDS Number: 1751221-00008
Date of last issue: 23.03.2020
Date of first issue: 14.06.2017

Section 1: Identification

Product name: Mometasone Ointment Formulation

Manufacturer or supplier's details
Company: Organon & Co.
Address: 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone: 551-430-6000
Emergency telephone number: 215-631-6999
E-mail address: EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

Section 2: Hazard identification

GHS Classification
Serious eye damage/eye irritation: Category 2A

GHS label elements
Hazard pictograms: ![Warning]
Signal word: Warning
Hazard statements: H319 Causes serious eye irritation.
Precautionary statements: Prevention:
P264 Wash skin thoroughly after handling.
P280 Wear eye protection/ face protection.
Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Other hazards which do not result in classification
None known.

Section 3: Composition/information on ingredients
SAFETY DATA SHEET
Mometasone Ointment Formulation

Version 2.1
Revision Date: 10.10.2020
SDS Number: 1751221-00008
Date of last issue: 23.03.2020
Date of first issue: 14.06.2017

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>8009-03-8</td>
<td>&gt;= 60 - &lt;= 100</td>
</tr>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>107-41-5</td>
<td>&gt;= 10 - &lt; 30</td>
</tr>
<tr>
<td>Propylene glycol monostearate</td>
<td>1323-39-3</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>&lt; 0.3</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice:
In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled:
If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact:
In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact:
In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed:
If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
Causes serious eye irritation.

Protection of first-aiders:
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media:
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during firefighting:
Vapours may form explosive mixtures with air.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides

Specific extinguishing method:
Use extinguishing measures that are appropriate to local cir-
SAFETY DATA SHEET

Mometasone Ointment Formulation

Version: 2.1  
Revision Date: 10.10.2020  
SDS Number: 1751221-00008  
Date of last issue: 23.03.2020  
Date of first issue: 14.06.2017

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures.
Conditions for safe storage:
- Keep in properly labelled containers.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>8009-03-8</td>
<td>WES-TWA (Mist)</td>
<td>5 mg/m3</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Further information: Sampled by a method that does not collect vapour.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>WES-STEI (Mist)</td>
<td>10 mg/m3</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>5 mg/m3</td>
<td>ACGIH</td>
</tr>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>107-41-5</td>
<td>WES-Ceiling</td>
<td>25 ppm</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>121 mg/m3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Vapour)</td>
<td>25 ppm</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL (Vapour)</td>
<td>50 ppm</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL (Inhalable fraction, Aerosol only)</td>
<td>10 mg/m3</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Propylene glycol monostearate</td>
<td>1323-39-3</td>
<td>WES-TWA</td>
<td>10 mg/m3</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m3</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m3</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m3 (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>10 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
- Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, vented enclosure, etc.).
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Personal protective equipment

Respiratory protection
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  
  Filter type: Combined particulates and organic vapour type

Hand protection
- Chemical-resistant gloves

Eye protection
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection
- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance: ointment

Colour: white to off-white

Odour: No data available

Odour Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: > 93.3 °C

Evaporation rate: No data available

Flammability (solid, gas): Not classified as a flammability hazard

Flammability (liquids): Not applicable

Upper explosion limit / Upper flammability limit: No data available
SAFETY DATA SHEET
Mometasone Ointment Formulation

Version 2.1  Revision Date: 10.10.2020  SDS Number: 1751221-00008  Date of last issue: 23.03.2020  Date of first issue: 14.06.2017

Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: No data available
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity
Viscosity, kinematic: No data available
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available

Section 10: Stability and reactivity
Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Vapours may form explosive mixture with air. Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

Section 11: Toxicological information
Exposure routes
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.
Components:

Petrolatum:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
   Method: OECD Test Guideline 401
   Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
   Method: OECD Test Guideline 402
   Assessment: The substance or mixture has no acute dermal toxicity
   Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
   Method: OECD Test Guideline 402
   Assessment: The substance or mixture has no acute dermal toxicity

Propylene glycol monostearate:
Acute oral toxicity: LD50 (Mouse): > 5,000 mg/kg

Mometasone:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
   LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 3.3 mg/l
   Exposure time: 4 h
   Test atmosphere: dust/mist
   Remarks: No mortality observed at this dose.

   LC50 (Mouse): > 3.2 mg/l
   Exposure time: 4 h
   Test atmosphere: dust/mist

Acute toxicity (other routes of administration): LD50 (Rat): 300 mg/kg
   Application Route: Subcutaneous
   Symptoms: Breathing difficulties

Skin corrosion/irritation
Not classified based on available information.

Components:

Petrolatum:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation
Remarks: Based on data from similar materials
2-Methyl-2,4-pentanediol:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Propylene glycol monostearate:
Result: No skin irritation

Mometasone:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

Petrolatum:
Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days

Mometasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Petrolatum:
Test Type: Buehler Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials
### SAFETY DATA SHEET

**Mometasone Ointment Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>10.10.2020</td>
<td>1751221-00008</td>
<td>23.03.2020</td>
<td>14.06.2017</td>
</tr>
</tbody>
</table>

**2-Methyl-2,4-pentanediol:**
- **Test Type:** Maximisation Test
- **Exposure routes:** Skin contact
- **Species:** Guinea pig
- **Method:** OECD Test Guideline 406
- **Result:** negative

**Mometasone:**
- **Test Type:** Maximisation Test
- **Exposure routes:** Dermal
- **Species:** Guinea pig
- **Assessment:** Does not cause skin sensitisation.
- **Result:** negative
- **Remarks:** The results of a test on guinea pigs showed this substance to be a weak skin sensitisier.

**Chronic toxicity**
**Germ cell mutagenicity**
Not classified based on available information.

### Components:

**Petrolatum:**
- Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro
  - Result: negative
  - Remarks: Based on data from similar materials

- Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Intraperitoneal injection
  - Method: OECD Test Guideline 474
  - Result: negative
  - Remarks: Based on data from similar materials

**2-Methyl-2,4-pentanediol:**
- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

  Test Type: In vitro mammalian cell gene mutation test
  - Method: OECD Test Guideline 476
  - Result: negative

  Test Type: Chromosome aberration test in vitro
  - Result: negative

**Mometasone:**
- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

  Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo:
Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity:
Not classified based on available information.

Components:

Petrolatum:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Mometasone:
Species: Rat
Application Route: Inhalation
Exposure time: 2 Years
Dose: 0.067 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Inhalation
Exposure time: 19 Months
Dose: 0.160 mg/kg body weight
Result: negative
**Reproductive toxicity**
Not classified based on available information.

### Components:

**Petrolatum:**
- **Effects on fertility**
  - Test Type: Reproduction/Developmental toxicity screening test
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative
  - Remarks: Based on data from similar materials

- **Effects on foetal development**
  - Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Skin contact
  - Result: negative
  - Remarks: Based on data from similar materials

**2-Methyl-2,4-pentanediol:**
- **Effects on fertility**
  - Test Type: Reproduction/Developmental toxicity screening test
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 421
  - Result: negative

- **Effects on foetal development**
  - Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 414
  - Result: negative

**Mometasone:**
- **Effects on fertility**
  - Test Type: Fertility
  - Species: Rat
  - Application Route: Subcutaneous
  - Fertility: NOAEL: 0.015 mg/kg body weight
  - Symptoms: Reduced embryonic survival, Reduced foetal weight
  - Result: No effects on fertility, Effect on reproduction capacity

- **Effects on foetal development**
  - Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Subcutaneous
  - Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight
  - Result: Embryotoxic effects, Teratogenicity and developmental toxicity

  - Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Dermal
  - Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight
  - Result: Embryo-foetal toxicity
SAFETY DATA SHEET
Mometasone Ointment Formulation

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Dermal
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure
Not classified based on available information.

Components:
Mometasone:
Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure
Not classified based on available information.

Components:
Mometasone:
Exposure routes : inhalation (dust/mist/fume)
Target Organs : Immune system, Liver, Kidney, Skin
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Petrolatum:
Species : Rat
NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

2-Methyl-2,4-pentanediol:
SAFETY DATA SHEET
Mometasone Ointment Formulation

Species: Rat
NOAEL: >= 450 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Method: OECD Test Guideline 408

Mometasone:
Species: Rat
NOAEL: 0.005 mg/kg
LOAEL: 0.3 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Dog
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Rat
NOAEL: 0.00013 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:

Mometasone: Not applicable

Experience with human exposure

Components:

2-Methyl-2,4-pentanediol:
Eye contact: Target Organs: Eyes
Symptoms: Irritation

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
SAFETY DATA SHEET

Mometasone Ointment Formulation

Version 2.1  Revision Date: 10.10.2020  SDS Number: 1751221-00008  Date of last issue: 23.03.2020  Date of first issue: 14.06.2017

Skin contact

Further information

Components:

Mometasone:
Remarks: Dermal absorption possible

Section 12: Ecological information

Ecotoxicity

Components:

Petrolatum:
Toxicity to fish
Toxicity to daphnia and other aquatic invertebrates
Toxicity to algae/aquatic plants

2-Methyl-2,4-pentanediol:
Toxicity to fish
Toxicity to daphnia and other aquatic invertebrates
Toxicity to algae/aquatic plants

Exposure time: 96 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Exposure time: 48 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Exposure time: 21 d
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Exposure time: 96 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Exposure time: 48 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
<table>
<thead>
<tr>
<th>Method</th>
<th>Concentration</th>
<th>Exposure Time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
<tr>
<td>Test Type: Respiration inhibition</td>
<td>NOEC: 1,000 mg/l</td>
<td>3 h</td>
<td>No toxicity at the limit of solubility</td>
</tr>
</tbody>
</table>
Persistence and degradability

Components:

Petrolatum:

2-Methyl-2,4-pentanediol:

Mometasone:

Stability in water : Hydrolysis: 50 % (12 d) Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

2-Methyl-2,4-pentanediol:
Partition coefficient: n-octanol/water : log Pow: 0 Remarks: Calculation

Mometasone:
Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

Mobility in soil

Components:

Mometasone:
Distribution among environmental compartments : log Koc: 4.02

Other adverse effects
No data available
Section 13: Disposal considerations

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9

IATA-DGR
UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Further information
Date format : dd.mm.yyyy

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants
ACGIH / TWA : 8-hour, time-weighted average
ACGIH / STEL : Short-term exposure limit
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average
NZ OEL / WES-STEL : Workplace Exposure Standard - Short-Term Exposure Limit
NZ OEL / WES-Ceiling : Workplace Exposure Standard - Ceiling
SAFETY DATA SHEET

Mometasone Ointment Formulation

Version 2.1  Revision Date: 10.10.2020  SDS Number: 1751221-00008  Date of last issue: 23.03.2020
Date of first issue: 14.06.2017

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN